This quality standard covers assessing if people need help with their medicines and deciding what medicines support is needed to enable people to manage their medicines. It also includes communication between health and social care staff, to ensure people have the medicines support they need. It describes high-quality care in priority areas for improvement.
This quality standard covers the developmental follow-up of babies, children and young people under 18 years who were born preterm (before 37+0 weeks of pregnancy). It describes high-quality care in priority areas for improvement.
This quality standard covers diagnosing and managing cystic fibrosis in infants, children, young people and adults. It describes high-quality care in priority areas for improvement.
This quality standard covers assessing and managing trauma (complex fractures, non-complex fractures, major trauma and spinal injury) in adults, young people and children. It describes high-quality care in priority areas for improvement.
This quality standard covers the prevention or delay of harmful use of drugs by children, young people and adults most likely to start using drugs, or already experimenting or using drugs occasionally. This includes illegal psychoactive substances, solvents, volatile substances, image- and performance-enhancing drugs, prescription-only medicines and over-the-counter medicines. It describes high-quality care in priority areas for improvement.
This quality standard covers the management of Parkinson’s disease in adults. It does not include treatment of parkinsonism not caused by Parkinson’s disease. It describes high-quality care in priority areas for improvement.
This quality standard covers recognising, assessing and managing mental health problems in adults (aged 18 and over) who are in contact with the criminal justice system (this includes police contact, court and prison custody, street triage, liaison and diversion services, and probation services). It describes high-quality care in priority areas for improvement.
This quality standard covers diagnosing, assessing and managing cerebral palsy in children and young people under 25. It describes high-quality care in priority areas for improvement.
This quality standard covers the recognition, diagnosis and early management of sepsis for all populations. It describes high-quality care in priority areas for improvement.
This quality standard covers end of life care for infants, children and young people (from birth to 18 years) who have a life-limiting condition. Life-limiting conditions are those that are expected to result in an early death for the person. It also covers support for family members and carers. It describes high-quality care in priority areas for improvement.
This quality standard covers diagnosing and managing hip fracture in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
This quality standard covers transitions for children, young people and adults between mental health hospitals and their own homes, care homes or other community settings. It includes the period before, during and after a person is admitted to, and discharged from, a mental health hospital. It describes high-quality care in priority areas for improvement.
This quality standard covers adults with rehabilitation needs as a result of critical illness that required level 2 or level 3 critical care. It describes high-quality care in priority areas for improvement.
This quality standard covers the diagnosis and management of cataracts, glaucoma and age-related macular degeneration (AMD) and the prevention of sight loss. It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on pembrolizumab (Keytruda) with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung
Evidence-based recommendations on darvadstrocel (Alofisel; stem-cell treatment) for complex perianal fistulas with mildly or non-active luminal Crohn’s disease
Evidence-based recommendations on regorafenib (Stivarga) for treating advanced hepatocellular carcinoma (liver cancer) in adults who have had sorafenib
Evidence-based recommendation on pembrolizumab (Keytruda) for adjuvant treatment of completely resected stage III melanoma with lymph node involvement in adults
Evidence-based recommendations on liposomal cytarabine–daunorubicin (Vyxeos) for untreated acute myeloid leukaemia (AML) in adults
Evidence-based recommendations on lenvatinib (Lenvima) for untreated advanced hepatocellular carcinoma (HCC) in adults
Evidence-based recommendations on vandetanib (Caprelsa) for treating medullary thyroid cancer in adults
NICE is unable to make a recommendation about the use in the NHS of denosumab for preventing skeletal-related events in multiple myeloma because no evidence
NICE is unable to make a recommendation about the use in the NHS of decitabine for untreated acute myeloid leukaemia because no evidence submission was
Evidence-based recommendations on tofacitinib (Xeljanz) for previously treated moderately to severely active ulcerative colitis in adults
Evidence-based recommendations on padeliporfin (Tookad) for untreated, unilateral, low-risk prostate cancer in adults
Evidence-based recommendations on emtuzumab oxogamicin (Mylotarg) for untreated acute myeloid leukaemia (AML) in people aged 15 years and over
Evidence-based recommendations on dabrafenib (Tafinlar) with trametinib (Mekinist) for resected stage III, BRAF V600 mutation-positive melanoma in adults
Evidence-based recommendations on tofacitinib (Xeljanz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults
Evidence-based recommendations on cabozantinib (Cabometyx) for untreated advanced renal cell carcinoma in adults
Evidence-based recommendations on inotuzumab ozogamicin (Besponsa) for relapsed/refractory CD22-positive B-cell precursor acute lymphoblastic leukaemia (ALL)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma (cHL) in adults
Evidence-based recommendations on lutetium (177Lu) oxodotreotide (Lutathera) for treating unresectable or metastatic neuroendocrine tumours in adults
Evidence-based recommendations on ixekizumab (Taltz) for treating active psoriatic arthritis after inadequate response to DMARDs in adults
NICE was unable to make a recommendation about the use in the NHS of tenofovir alafenamide for treating chronic hepatitis B because no evidence submission was
NICE was unable to make a recommendation about the use in the NHS of elotuzumab for previously treated multiple myeloma because no evidence submission was
Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis in adults
Evidence-based recommendations on everolimus (Afinitor) for advanced renal cell carcinoma (kidney cancer) after previous treatment
Evidence-based recommendations on mepolizumab (Nucala) for treating severe refractory eosinophilic asthma in adults
Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults
Evidence-based recommendations on ibrutinib (Imbruvica) for treating chronic lymphocytic leukaemia in adults
Evidence-based recommendations on avelumab (Bavencio) for treating metastatic (secondary) Merkel cell carcinoma (skin cancer) in adults
Evidence-based recommendations on cabozantinib (Cometriq) for treating medullary thyroid cancer (MTC) in adults
Evidence-based recommendations on eribulin (Halaven) for treating locally advanced or metastatic (secondary) breast cancer in adults who have had only 1 course
Evidence-based recommendations on tivozanib (Fotivda) for previously untreated advanced renal cell carcinoma (RCC/kidney cancer) in adults
Evidence-based recommendations on daratumumab (Darzalex) for relapsed or refractory multiple myeloma in adults
Evidence-based recommendations on autologous chondrocyte implantation (ACI) using chondrosphere (Spherox) for symptomatic articular knee cartilage defects
Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C (HCV) in adults
Evidence-based recommendations on lesinurad (Zurampic) for treating chronic hyperuricaemia (too much uric acid/urate in blood) in adults with gout
Evidence-based recommendations on ixazomib (Ninlaro) with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Evidence-based recommendations on pirfenidone (Esbriet) for idiopathic pulmonary fibrosis (IPF) in adults